CONVERT试验中放疗方案变异与结局的关联
该研究对CONVERT III期试验中随机抽取的93例患者进行回顾性放疗质量保证(QA)审查,重新勾画心脏、肺和脊髓危及器官并重新采集剂量学数据,将方案变异分为可接受、可接受变异和不可接受变异。结果显示不可接受变异与急性≥3级毒性、无进展生存(PFS)或总生存(OS)均无显著关联,但非方案依从的心脏勾画与心脏OAR剂量增加相关,11.8%的病例心脏结构超出方案定义的剂量约束。
要点
- 97.8%的大体肿瘤体积(GTV)勾画符合方案,但心脏、肺和脊髓OAR勾画的不符合率分别为79.6%、37.6%和75.3%。
- 11.8%的提交病例超出方案定义的心脏剂量约束,其中6例仅在应用方案依从勾画时才发现。
- 不可接受变异与≥3级毒性(p=0.808)、PFS(p=0.232)或OS(p=0.743)均无显著关联。
核心结论
- 非方案依从的心脏勾画与心脏OAR剂量增加相关,11.8%的提交心脏结构超出方案定义的约束。
- 在该小细胞肺癌QA队列中,不可接受变异与急性≥3级毒性、PFS或OS无显著关联。
- 放疗QA仍是高质量放疗实施的基础,应嵌入临床试验和非临床试验实践;临床试验应报告标准化的放疗QA参数及试验结局。
研究设计与样本
- CONVERT III期试验的回顾性放疗QA审查,随机抽取100例患者请求放疗计划数据,最终93例提交审查。
- CONVERT试验管理组(TMG)成员按试验指南重新勾画心脏、肺和脊髓OAR,将原放疗计划应用于新结构并重新采集剂量学数据。
- 记录放疗QA各组成部分的依从性,并汇总为方案变异:可接受、可接受变异和不可接受变异。
- 采用Cox比例风险模型进行单变量分析,建立方案变异与患者结局的关系。
主要发现
- 放疗QA队列(n=93)的人口统计学特征与非QA队列(n=450)相匹配。
- 97.8%的GTV勾画符合方案;OAR勾画不符合率:心脏79.6%、肺37.6%、脊髓75.3%。
- 不符合心脏勾画中,86.5%在方案定义心脏边界的尾侧和2.7%在颅侧超出边界;10.8%未包括心包囊,2.7%未包括心包前部。
- 11例(11.8%)提交病例超出方案定义的心脏剂量约束,其中6例仅在应用方案依从勾画时发现。
- 不可接受变异与≥3级毒性增加(p=0.808)、PFS(p=0.232)或OS(p=0.743)均无显著关联。
关键数值与推荐
- GTV勾画方案依从率为97.8%。
- 心脏OAR勾画不符合率为79.6%,其中86.5%尾侧超出和2.7%颅侧超出方案定义边界,10.8%未包括心包囊,2.7%未包括心包前部。
- 肺OAR勾画不符合率为37.6%,脊髓OAR勾画不符合率为75.3%。
- 11.8%的提交病例心脏结构超出方案定义的剂量约束。
- 不可接受变异与≥3级毒性(p=0.808)、PFS(p=0.232)、OS(p=0.743)的关联均无统计学显著性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy quality assurance (QA) is integral to radiotherapy delivery. Here we report comprehensive contouring, dosimetry, and treatment delivery QA, describe protocol compliance, and detail the impact of protocol variations on acute grade ≥3 toxicity, progression free survival (PFS), and overall survival (OS) in the phase III CONVERT trial. MATERIALS/METHODS: Radiotherapy planning data from one hundred randomly selected patients were requested. Members of the CONVERT Trial Management Group (TMG) recontoured the heart, lung, and spinal cord organs at risk (OAR) according to the trial guideline. The existing radiotherapy plan were re-applied to the new structures and the new dosimetric data were recollected. Compliance with radiotherapy QA components were recorded and radiotherapy QA components were pooled into protocol variations: acceptable, acceptable variation, and unacceptable variation. Univariable analysis with a Cox proportional hazards model established the relationship between protocol variations and patient outcome. RESULTS: Ninety-three cases were submitted for retrospective radiotherapy QA review. Demographics of the radiotherapy QA cohort (n=93) matched the non-QA (n=450) cohort. 97.8% of gross tumour volume (GTV) contours were protocol compliant. OAR contours were non-compliant in 79.6% instances of the heart, 37.6% lung, and 75.3% spinal cord. Of the non-compliant heart contours, 86.5% and 2.7% had contours caudal and cranial to the protocol-defined heart borders. 10.8% did not include the pericardial sac and 2.7% did not include the anterior aspect of the pericardium. Eleven (11.8%) submissions exceeded protocol-defined dosimetric heart constraints; six of which were only noted on the application of protocol-compliant contours. Unacceptable variations were not associated with an increase in grade 3 toxicity (p=0.808), PFS (p=0.232), or OS (p=0.743). CONCLUSION: Non-protocol compliant heart contours were associated with increased dose delivered to the heart OAR, with 11.8 % of submitted heart structures exceeding protocol-defined constraints. In this QA cohort of patients with small cell lung cancer, unacceptable variations were not associated with acute grade ≥3 toxicity, PFS, or OS. Radiotherapy QA remains the cornerstone of high-quality radiotherapy delivery and should be embedded into clinical trial and non-clinical trial practice; clinical trials should report standardised radiotherapy QA parameters alongside trial outcomes.
引用
- Mir R, Groom N, Mistry HB, et al. Association between radiotherapy protocol variations and outcome in the CONVERT trial. Clin Transl Radiat Oncol. 2022. PMID: 36578530. doi:10.1016/j.ctro.2022.100560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。